title: Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations.
abstract: BACKGROUND
  Left ventricular hypertrophy (LVH) measured by echocardiography is a powerful independent marker of increased cardiovascular risk. The prevalence of echocardiographic LVH in patients with high cardiovascular risk appears to be high, even in patients currently considered normotensive.
  
  
  OBJECTIVE
  To ascertain the likely costs of screening for and treating echocardiographic LVH in normotensive patients at high risk of cardiovascular events.
  
  
  METHODS
  Hypothetical economic analysis.
  
  
  METHODS
  Cost analyses were based on known costs of echocardiography, costs of selected cardiovascular medications and prevalence of normotensive LVH in at-risk populations, combined with treatment effect data from studies of hypertensive patients with echocardiographic LVH.
  
  
  RESULTS
  Screening costs per case for echocardiographic LVH are likely to be low, because of the high prevalence of the condition and the low unit cost of echocardiography. Treatment costs are likely to be comparable to those currently deemed acceptable in treating high-risk cardiovascular populations, e.g. the HOPE study population.
  
  
  CONCLUSIONS
  The costs of screening for and treating LVH in normotensive patients at risk of cardiovascular events do not appear to be prohibitively high. Trials of screening and treatment for normotensive LVH seem therefore to be warranted.
authors.affiliation: Section of Ageing and Health, Ninewells Hospital and Medical School, Dundee, UK. m.witham@dundee.ac.uk
authors.forename: M D
authors.initials: MD
authors.lastname: Witham
authors.forename: J I
authors.initials: JI
authors.lastname: Davies
authors.forename: A
authors.initials: A
authors.lastname: Dawson
authors.forename: P G
authors.initials: PG
authors.lastname: Davey
authors.forename: A D
authors.initials: AD
authors.lastname: Struthers
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002752:Chlorthalidone / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004452:Echocardiography / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000191:economics*; D019808:Losartan / Q000627:therapeutic use; D008403:Mass Screening / Q000191:economics*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D019808:Losartan; D002752:Chlorthalidone